Based on the recent earnings conference call transcript, AmerisourceBergen Corp. has shown solid performance in key financial metrics and has provided guidance for fiscal year 2018. The company's adjusted diluted EPS for Q4 2017 was $1.33, a 2% increase in line with expectations. Consolidated revenues were $39 billion, up 4%, with a 7% growth when adjusting for the impact of lower hepatitis C revenues and one less business day in the quarter. The adjusted operating income was $471 million, up 1.5%, while the adjusted net income decreased by about 1% to $293 million. The company achieved a record free cash flow of nearly $1.3 billion for the quarter. For fiscal year 2017, the company's revenue growth was 4%, with adjusted operating income almost flat at about $2 billion and adjusted diluted EPS at $5.88, up about 5%. The company ended the year with strong financial flexibility and a strong balance sheet.

For fiscal year 2018, AmerisourceBergen Corp. expects consolidated revenue growth in the 7% to 9% range. Additionally, the company expects a 3% to 5% increase in adjusted operating income, with adjusted EPS ranging from $5.90 to $6.15. The guidance also includes expectations for modest share buybacks and a full year adjusted tax rate of about 32% to 33%. Capital expenditures are expected to be about $325 million. The company remains focused on streamlining and gaining efficiencies in a rapidly evolving U.S. healthcare market, and anticipates benefits from technology investments and the onboarding of the Walgreens Rite Aid business.

Overall, AmerisourceBergen Corp. continues to navigate the challenges of the healthcare environment and remains confident in its overall strategy to drive sustainable growth. As a financial analyst, considering the strong financial performance and guidance provided by the company, an 'overweight' investment stance can be adopted, with cautious attention to industry challenges and the company's efforts to mitigate these challenges through strategic investments and initiatives.